$DBVT News

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside

DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

DBV Technologies Q2 Earnings Call Highlights

DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

DBV Technologies Q2 EPS $(0.12) Misses $(0.10) Estimate, Sales $700.000K Miss $1.391M Estimate

DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index

DBV Technologies (ENXTPA:DBV) Advances Peanut Patch With New Phase 3 Data And Infant Trial

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

DBV Technologies To Present New Data From VITESSE Study And Preview Recently Initiated THRIVE Study At EAACI Congress 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026

DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies Starts Infant Study of Peanut Allergy Patch